Back to search results

DAW2020 for Obstructive Sleep Apnea (OSA) Endotypic Traits

This study is looking at how DAW2020, an oral capsule, affects Obstructive Sleep Apnea (OSA) in people aged 21 to 70. OSA is a common condition where breathing repeatedly stops and starts during sleep. Researchers want to see if DAW2020 can help with a specific OSA trait called "arousal threshold," which is how easily someone wakes up during a breathing problem. You could be eligible if you have moderate-to-severe OSA (meaning you have at least 15 breathing interruptions per hour) and are generally healthy. The study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design
This is an interventional study with 20 participants, comparing DAW2020 to a placebo (an inactive capsule). It involves two overnight sleep studies.
What's involved
You would have two overnight stays at a sleep lab, where you'll be monitored for sleep and breathing. There will be a one-week break between the two overnight stays.
Compensation
Not stated in the trial record.
Follow-up
The primary effect of DAW2020 is measured after one night of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04538755

DAW2020 on OSA Endotypic Traits

Enrolling by Invitation
PHASE1Ages 21–70InterventionalTreatment
Brigham and Women's Hospital
~20 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Placebo oral capsuleDAW2020 oral capsule

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effects of DAW2020 on arousal threshold (%eupnea)
Measured over 1 night

Conditions

Obstructive Sleep Apnea (OSA)

Explore related trials

Obstructive Sleep Apnea

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Moderate-to-severe OSA (AHI ≥ 15 events/hr)

Exclusion

All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements.
Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
Use of SNRIs/SSRIs.
Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias.
Hypersensitivity to the study drug (angioedema or urticaria)
Contraindications to DAW2020
Use of medications that lengthen QTc interval
Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
Severe claustrophobia.

What this trial measures

  • Effects of DAW2020 on arousal threshold (%eupnea)1 night

    Arousal threshold will be calculated using diaphragm EMG